Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (DFPH) Depreciation & Amortization (CF) (2021 - 2025)

Historic Depreciation & Amortization (CF) for Oncology Institute (DFPH) over the last 5 years, with Q3 2025 value amounting to $1.7 million.

  • Oncology Institute's Depreciation & Amortization (CF) rose 953.59% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 1400.03%. This contributed to the annual value of $6.3 million for FY2024, which is 704.92% up from last year.
  • Per Oncology Institute's latest filing, its Depreciation & Amortization (CF) stood at $1.7 million for Q3 2025, which was up 953.59% from $1.8 million recorded in Q2 2025.
  • Over the past 5 years, Oncology Institute's Depreciation & Amortization (CF) peaked at $1.8 million during Q2 2025, and registered a low of $777000.0 during Q1 2021.
  • Its 5-year average for Depreciation & Amortization (CF) is $1.3 million, with a median of $1.3 million in 2023.
  • Per our database at Business Quant, Oncology Institute's Depreciation & Amortization (CF) skyrocketed by 4973.54% in 2023 and then plummeted by 736.16% in 2024.
  • Oncology Institute's Depreciation & Amortization (CF) (Quarter) stood at $920000.0 in 2021, then rose by 29.57% to $1.2 million in 2022, then soared by 32.3% to $1.6 million in 2023, then grew by 8.24% to $1.7 million in 2024, then grew by 0.94% to $1.7 million in 2025.
  • Its Depreciation & Amortization (CF) was $1.7 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.8 million in Q1 2025.